<DOC>
	<DOC>NCT02887625</DOC>
	<brief_summary>To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea</brief_summary>
	<brief_title>Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM</brief_title>
	<detailed_description>poorly controlled (HbA1c &gt;7.5%) T2DM patients (18-75 years of age) on maximal/near maximal dose of sulfonylurea plus metformin who otherwise are healthy will be randomized to receive: 1. exenatide weekly injection (2 mg/week) 2. glargine insulin plus insulin aspart which will be titrated to maintain HbA1c &lt;7.0%</detailed_description>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>T2DM poorly controlled (HbA1c &gt;7.5%) on metformin (&gt;1700 mg/day) plus sulfonylurea type 1 diabetes (T1DM) patients receiving therapy with pioglitazone, GLP1 RA and insulin abnormal kidney, liver or heart function patients with malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>